Top 3 Picks
2026 Outlook
The diagnostics sector is expected to experience robust growth through 2026, with projections indicating a compound annual growth rate (CAGR) of around 8-10% driven by increasing adoption of AI-powered tools and point-of-care testing. Emerging trends such as at-home diagnostics and integration with telehealth will enhance accessibility and efficiency, potentially expanding the market to over $100 billion by 2026. Investors should monitor regulatory approvals and R&D investments, as these factors will shape the sector's ability to capitalize on personalized medicine and global health initiatives.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Neogen Corp
|
65.2 | $7.26 | $1.3B |
|
2
|
QuidelOrtho Corporation Common Stock
|
60.4 | $30.06 | $2.1B |
|
3
|
Lantheus Holdings, Inc
|
59.6 | $68.98 | $3.5B |
|
4
|
Achieve Life Sciences, Inc.
|
59.4 | $5.19 | $158M |
|
5
|
BIOMERICA INC
|
59.1 | $2.60 | $8M |
|
6
|
Insight Molecular Diagnostics Inc. Common Stock
|
58.7 | $7.47 | $94M |
|
7
|
Idexx Laboratories Inc
|
58.6 | $682.23 | $49.6B |
|
8
|
Celldex Therapeutics, Inc
|
56.1 | $25.60 | $1.7B |
|
9
|
Myriad Genetics Inc
|
56.0 | $6.14 | $719M |
|
10
|
Cardio Diagnostics Holdings Inc. Warrant
|
55.0 | $0.02 | -- |
|
11
|
VolitionRX Limited Common Stock
|
53.2 | $0.28 | $67M |
|
12
|
Immucell Corp
|
52.2 | $6.05 | $60M |
|
13
|
Intellia Therapeutics, Inc
|
51.5 | $9.37 | $2.0B |
|
14
|
Q/C Technologies, Inc. Common Stock
|
47.3 | $4.54 | $8M |
|
15
|
Cardio Diagnostics Holdings Inc. Common stock
|
46.6 | $2.98 | $8M |
In-Depth Analysis: Top Diagnostics Stocks
NEOG
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged …
Neogen Corporation is a pivotal player in the Diagnostics sector, specializing in food and animal safety products that detect contaminants and pathogens, thereby preventing foodborne illnesses and ensuring compliance with global safety standards. Its diagnostic solutions address critical public health needs, positioning it as essential in an industry increasingly focused on regulatory and consumer-driven safety demands.
Neogen's profitability is severely challenged, with a profit margin of -117.6% indicating substantial operational losses and an ROE of -39.7% reflecting inefficient use of shareholder equity, which highlights financial strain. Despite a revenue growth decline of -3.6%, the Tradestie Score of 65.2 suggests moderate underlying potential, though overall financial health remains weak and requires improvement for sustainability.
By 2026, Neogen could capitalize on the expanding global diagnostics market for food safety, where increasing regulatory demands and population growth may drive demand for its contaminant detection products, potentially reversing the current -3.6% revenue decline. The company's Tradestie Score of 65.2 indicates a reasonable investment foundation, and ongoing innovations in diagnostics could enhance profitability, making it an attractive option for long-term investors seeking exposure to essential health and safety sectors. With its established market presence, Neogen is positioned for recovery if it effectively addresses current financial weaknesses.
QDEL
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue …
QuidelOrtho Corporation stands out in the Diagnostics sector for its comprehensive development and marketing of rapid diagnostic testing solutions, including immunoassay, molecular testing, clinical chemistry, and transfusion medicine, which enable clinicians and patients to make informed decisions globally. This expertise positions the company as a key player in addressing worldwide healthcare needs, particularly in rapid response scenarios like pandemics.
QuidelOrtho's profitability is strained, evidenced by a -43.5% profit margin and -45.2% ROE, indicating significant losses and poor returns on shareholder equity that highlight financial challenges. Despite a -3.7% revenue growth, these metrics suggest the company is navigating sector volatility, potentially impacting long-term financial health without strategic improvements.
By 2026, investors should consider QDEL due to anticipated growth in the diagnostics sector, driven by increasing global demand for advanced testing solutions amid rising health awareness and potential market recovery from recent declines. The company's diversified portfolio in immunoassay and molecular testing could capitalize on innovations like personalized medicine, positioning it for revenue rebound from the current -3.7% growth. Furthermore, with a Tradestie Score of 60.4, indicating moderate potential, improved operational efficiencies could lead to enhanced profitability and stock appreciation.
LNTH
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic …
Lantheus Holdings Inc is a significant contributor to the Diagnostics sector, offering innovative products in Precision Diagnostics and Radiopharmaceutical Oncology that enhance accurate disease detection and personalized treatment in the US healthcare system. Its strategic partnerships further bolster its revenue diversification, positioning the company as a key enabler of advanced diagnostic solutions amid growing demand for precision medicine.
Lantheus exhibits moderate profitability with an 11.0% profit margin and a 14.6% ROE, indicating efficient equity utilization and sustainable earnings generation despite a low 1.4% revenue growth rate. The 27.9 P/E ratio reflects market optimism for future expansion, suggesting the company maintains solid financial health in a competitive sector.
By 2026, LNTH's focus on Radiopharmaceutical Oncology could capitalize on the expanding cancer diagnostics market, potentially accelerating revenue growth beyond the current 1.4% as demand for precision therapies rises. The company's strong 14.6% ROE demonstrates effective profit generation from equity, supporting long-term value creation. Additionally, with a Tradestie Score of 59.6 indicating moderate upside, strategic partnerships may drive further innovation and market share gains, making it an attractive buy for investors seeking exposure to healthcare advancements.
ACHV
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It …
Achieve Life Sciences matters in the Diagnostics sector by advancing cytisinicline as a smoking cessation treatment, which addresses nicotine addiction and supports broader public health diagnostics for addiction-related diseases. Its established approval and marketing in Central and Eastern Europe demonstrate a proven track record that could expand to enhance global diagnostic and therapeutic approaches for smoking-related health issues.
The company's ROE of -161.1% indicates severe profitability challenges, reflecting significant losses relative to shareholders' equity and highlighting financial instability. However, a Tradestie Score of 59.4/100 suggests moderate operational strengths, potentially offering a pathway for improvement if clinical advancements translate into revenue growth.
By 2026, Achieve Life Sciences could see substantial growth from potential FDA approval of cytisinicline, expanding its market beyond Europe and tapping into the growing $1.5 billion global smoking cessation market, which is projected to grow at a 7% CAGR. The company's established efficacy in treating nicotine addiction positions it for increased adoption, potentially driving stock value through partnerships or acquisitions. Additionally, with ongoing clinical trials, successful outcomes could lead to higher revenue streams, making ACHV an attractive buy for investors focused on innovative health solutions.
BMRA
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, …
Biomerica Inc stands out in the Diagnostics sector for its specialized focus on developing and marketing products for early detection of chronic diseases such as gastrointestinal issues, food intolerances, and diabetes, addressing critical unmet needs in an aging global population. This positioning allows the company to contribute significantly to preventive healthcare, potentially reducing long-term medical costs through timely interventions.
Biomerica's profitability is severely challenged, with a profit margin of -74.8% indicating substantial operational losses, and an ROE of -69.6% reflecting inefficient use of shareholder equity. Additionally, the company's revenue growth of -23.6% underscores declining sales, highlighting financial instability that could hinder long-term sustainability without strategic improvements.
By 2026, the growing demand for diagnostic tools in chronic disease management, driven by an aging population and increasing prevalence of conditions like diabetes, could position Biomerica for recovery if they successfully innovate their product pipeline. The Tradestie Score of 59.1 suggests moderate potential, and potential advancements in at-home testing technologies may boost revenue growth from its current -23.6% trajectory. Investors might consider this stock for its niche in gastrointestinal diagnostics, offering upside if market partnerships or regulatory approvals enhance market penetration.
IMDX
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic …
Insight Molecular Diagnostics Inc. matters in the Diagnostics sector due to its innovative focus on democratizing access to molecular diagnostic testing via donor-derived cell-free DNA (dd-cfDNA) technology, which enables early detection and personalized medicine for improved patient outcomes. This positions the company as a key player in advancing precision diagnostics, potentially transforming healthcare delivery in an industry projected to grow rapidly.
Despite an impressive revenue growth of 1114.8%, indicating strong market traction and scaling potential, the company's ROE of -429.0% reveals significant profitability challenges, likely stemming from high R&D and operational expenses that are common in early-stage diagnostics firms.
By 2026, IMDX's exceptional revenue growth of 1114.8% suggests substantial market expansion and adoption of its dd-cfDNA technology, potentially capturing a larger share in the diagnostics sector amid rising demand for personalized medicine. The company's mission to enhance patient outcomes could lead to strategic partnerships or regulatory approvals, driving stock appreciation. With a Tradestie Score of 58.7, indicating moderate investment appeal, the high growth trajectory outweighs current financial weaknesses, making it a compelling buy for long-term investors.
IDXX
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet …
Idexx Laboratories matters in the Diagnostics sector as a leading provider of innovative veterinary diagnostic products, including single-use test kits and benchtop analyzers, which enable rapid and accurate disease detection for pets and livestock. This positions the company as a key player in the growing animal health market, addressing increasing demand for advanced diagnostics amid rising pet ownership and livestock health concerns.
Idexx demonstrates strong profitability with a 24.6% profit margin and an exceptional 64.6% ROE, indicating efficient use of equity and robust financial health. Despite a high P/E ratio of 53.2, the company's 13.3% revenue growth reflects solid expansion and operational effectiveness.
Idexx's 13.3% revenue growth highlights its potential for continued expansion in the diagnostics sector, driven by increasing demand for pet and livestock health solutions, making it a compelling investment by 2026. The company's impressive 64.6% ROE suggests strong shareholder returns and efficient capital allocation, likely supporting sustained value creation. Furthermore, with a solid 24.6% profit margin, Idexx is well-equipped to navigate market opportunities and deliver long-term gains for investors in 2026.
CLDX
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing …
Celldex Therapeutics Inc stands out in the diagnostics sector by advancing immunotherapy technologies that integrate with cancer diagnostics, potentially enabling more precise treatment selections for breast cancer, metastatic melanoma, and lung cancer through its biologics pipeline.
The company's ROE of -32.4% indicates significant losses relative to shareholder equity, reflecting challenges in generating returns amid high R&D costs, while a revenue growth of -70.8% highlights a sharp decline, likely due to the early-stage nature of its clinical trials, underscoring ongoing financial strain.
By 2026, Celldex's ongoing clinical trials for breast cancer, metastatic melanoma, and lung cancer could yield successful outcomes, potentially leading to FDA approvals and substantial revenue growth from new therapies. The Tradestie Score of 56.1 suggests moderate upside potential, supported by the expanding immunotherapy market projected to reach over $150 billion by 2026. Additionally, if the company achieves key milestones in its pipeline, it could attract partnerships or acquisitions, driving stock appreciation.
MYGN
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to …
Myriad Genetics Inc is a key player in the Diagnostics sector due to its specialized molecular diagnostic tests, such as the MyRisk 48-gene panel that identifies risks for 11 types of cancer, enabling personalized medicine and early disease prevention. This focus on genetic risk assessment positions the company at the forefront of a growing market for precision diagnostics, addressing critical healthcare needs amid rising cancer rates.
Myriad Genetics demonstrates significant financial strain with a profit margin of -48.5% and a return on equity of -72.5%, indicating substantial losses and inefficient equity utilization that undermine shareholder returns. The -3.6% revenue growth further highlights operational challenges, suggesting the company is struggling to expand sales in a competitive diagnostics landscape.
By 2026, Myriad Genetics could rebound as the global diagnostics market for genetic testing expands, driven by increasing demand for cancer risk assessments like MyRisk amid rising healthcare expenditures and aging populations. The company's innovative 48-gene panel offers potential for greater adoption with advancements in genomics and regulatory approvals, potentially improving revenue streams. Despite a Tradestie Score of 56.0, the firm's strategic position in personalized medicine may attract investors seeking long-term growth opportunities in the sector.
CDIOW
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood …
Cardio Diagnostics Holdings Inc. matters in the Diagnostics sector due to its innovative use of epigenetics and AI to develop clinical tests for cardiovascular diseases, addressing a major global health challenge that affects over 17.9 million people annually according to World Health Organization data. Their AI-powered solutions for risk assessment, detection, and management could transform personalized medicine by enabling earlier interventions and more precise monitoring.
With limited financial data available, Cardio Diagnostics exhibits a Tradestie Score of 55.0/100, indicating moderate financial health and potential operational efficiency in a high-growth sector, though this score suggests challenges in achieving immediate profitability. This reflects a company in its early stages, where investments in R&D for AI and epigenetics technologies may precede scalable revenue streams.
By 2026, Cardio Diagnostics is poised for growth as the global cardiovascular diagnostics market is projected to exceed $50 billion, driven by increasing adoption of AI technologies, potentially boosting demand for their innovative tests. Their epigenetics-based solutions could differentiate them in a competitive landscape, leading to partnerships and expanded market share. Furthermore, advancements in AI integration may enhance product efficacy, positioning the stock for appreciation amid rising healthcare digitization trends.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.